公开(公告)号：US11685702B2

公开(公告)日：2023-06-27

申请号：US17113695

申请日：2020-12-07

Applicant: JSI Silicone Co.

Inventor： Il Nam Jung ,  A Ra Cho ,  Seung Hwan Kang ,  Young Min Kim

IPC: C07C2/86 ,  C07C17/266 ,  C07C15/50 ,  C07C15/58 ,  C07C25/24 ,  C07C15/60 ,  C07C45/69 ,  C07C49/796 ,  C07C15/62 ,  C07C43/285 ,  C07C41/30 ,  C07C15/24 ,  C07C15/16 ,  C07C15/20 ,  C07F7/18 ,  C07C319/20 ,  C07C321/28 ,  C07F7/12 ,  C07C15/44

CPC classification number: C07C2/861 ,  C07C15/16 ,  C07C15/20 ,  C07C15/24 ,  C07C15/44 ,  C07C15/50 ,  C07C15/58 ,  C07C15/60 ,  C07C15/62 ,  C07C17/266 ,  C07C25/24 ,  C07C41/30 ,  C07C43/285 ,  C07C45/69 ,  C07C49/796 ,  C07C319/20 ,  C07C321/28 ,  C07F7/12 ,  C07F7/127 ,  C07F7/1804 ,  C07F7/1892 ,  C07C2603/24 ,  C07C2603/50 ,  C07C2603/52

Abstract: Provided is a method for producing (alkyl)arene compounds represented by Formulae 3-1, 3-2, and 3-3 by the Friedel-Crafts alkylation reaction of alkyl halide compounds and arene compounds using organic phosphine compounds as a catalyst.

公开(公告)号：US20160251307A1

公开(公告)日：2016-09-01

申请号：US14905776

申请日：2014-09-05

Applicant: PELOTON THERAPEUTICS, INC.

Inventor： Darryl David DIXON ,  Jonas GRINA ,  John A. JOSEY ,  James P. RIZZI ,  Stephen T. SCHLACHTER ,  Eli M. WALLACE ,  Bin WANG ,  Paul WEHN ,  Rui XU ,  Hanbiao YANG

IPC: C07C311/29 ,  C07D213/85 ,  C07C381/10 ,  C07C317/22

CPC classification number: C07D213/85 ,  A61K31/09 ,  A61K31/10 ,  A61K41/0038 ,  A61P35/00 ,  C07C43/205 ,  C07C43/225 ,  C07C43/23 ,  C07C43/263 ,  C07C43/275 ,  C07C43/285 ,  C07C43/29 ,  C07C205/22 ,  C07C255/54 ,  C07C255/56 ,  C07C311/29 ,  C07C313/06 ,  C07C317/22 ,  C07C317/24 ,  C07C317/32 ,  C07C317/34 ,  C07C317/36 ,  C07C317/40 ,  C07C317/42 ,  C07C317/44 ,  C07C317/46 ,  C07C317/48 ,  C07C323/22 ,  C07C381/10 ,  C07C2602/04 ,  C07C2602/08 ,  C07C2602/10 ,  C07C2603/94 ,  C07D213/65 ,  C07D213/89 ,  C07D231/56

Abstract: The present disclosure relates to HIF-2α inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2α scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.

Abstract translation: 本公开涉及HIF-2α抑制剂及其制备和使用它们用于治疗癌症的方法。 某些化合物在HIF-2α闪烁亲近测定，荧光素酶测定和VEGF ELISA测定中是有效的，并且导致体内在786-O异种移植小鼠中的肿瘤尺寸减小和消退。

公开(公告)号：US20130076604A1

公开(公告)日：2013-03-28

申请号：US13701665

申请日：2011-05-26

Applicant: Jun Kamatani ,  Naoki Yamada ,  Kengo Kishino ,  Akihito Saitoh

Inventor： Jun Kamatani ,  Naoki Yamada ,  Kengo Kishino ,  Akihito Saitoh

IPC: C07C13/62 ,  C07D215/06 ,  C07D213/06 ,  C07D213/16 ,  C07C25/22 ,  G09G3/32 ,  C07F7/08 ,  C07C43/285 ,  C07D333/54 ,  H01L51/00 ,  H01L27/32 ,  C07C211/61 ,  C07D209/86

CPC classification number: C07C13/62 ,  C07C25/22 ,  C07C43/285 ,  C07C211/61 ,  C07C2603/54 ,  C07D209/86 ,  C07D213/06 ,  C07D213/16 ,  C07D215/06 ,  C07D333/54 ,  C07F7/0805 ,  C09K11/06 ,  C09K2211/1011 ,  C09K2211/1029 ,  C09K2211/1037 ,  G09G3/3208 ,  H01L27/3225 ,  H01L51/0032 ,  H01L51/0056 ,  H01L51/0058 ,  H01L51/006 ,  H01L51/5012 ,  H05B33/14

Abstract: Provided are a novel organic compound appropriate for emission of green light and an organic light-emitting device including the organic compound. Provided is a substituted or unsubstituted indeno[1,2,3-cd]naphtho[2,3-k]fluoranthene appropriate for emission of green light. The substituents of the indeno[1,2,3-cd]naphtho[2,3-k]fluoranthene are each independently selected from a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted amino group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heterocyclic group.

Abstract translation: 提供适用于绿光发射的新型有机化合物和包含该有机化合物的有机发光装置。 提供适于发出绿光的取代或未取代的茚并〔1,2,3-cd〕萘并[2,3-k]荧蒽。 茚并[1,2,3-cd]萘并[2,3-k]荧蒽的取代基各自独立地选自氢原子，卤素原子，取代或未取代的烷基，取代或未取代的烷氧基， 取代氨基，取代或未取代的芳基和取代或未取代的杂环基。

公开(公告)号：US20090247798A1

公开(公告)日：2009-10-01

申请号：US12416451

申请日：2009-04-01

Applicant: Yoshikazu Miyamoto ,  Nobuyuki Miyaki ,  Kohei Goto ,  Yuichi Hashiguchi

Inventor： Yoshikazu Miyamoto ,  Nobuyuki Miyaki ,  Kohei Goto ,  Yuichi Hashiguchi

IPC: C07C13/567

CPC classification number: C07C43/215 ,  C07C13/72 ,  C07C25/24 ,  C07C43/285 ,  C07C2603/97 ,  C08G61/06

Abstract: The norbornene derivative of the present invention is represented by the following formula (Im). According to the present invention, a novel norbornene derivative that is useful as a precursor monomer for preparing a cycloolefin polymer exhibiting excellent transparency, heat resistance and low-water absorption properties and having been freely controlled in the birefringence properties and the wavelength dispersion properties can be provided. According to the present invention, further, a norbornene ring-opened (co)polymer having excellent transparency and heat resistance, exhibiting high solubility in organic solvents and having specific birefringence properties and wavelength dependence, and a process for preparing the ring-opened (co)polymer can be provided.

Abstract translation: 本发明的降冰片烯衍生物由下式（Im）表示。 根据本发明，作为用于制备具有优异的透明性，耐热性和低吸水性的环烯烃聚合物的前体单体的新型降冰片烯衍生物可以在双折射性和波长分散性中自由控制， 提供。 根据本发明，另外，具有优异的透明性和耐热性，在有机溶剂中显示出高溶解性并具有特定的双折射性和波长依赖性的降冰片烯开环（共）聚合物，以及制备开环（共 ）聚合物。

公开(公告)号：US06258909B1

公开(公告)日：2001-07-10

申请号：US09167827

申请日：1998-10-07

Applicant: Boris A. Zaitsev

Inventor： Boris A. Zaitsev

IPC: C08J3614

CPC classification number: C08F212/34 ,  C07C43/285 ,  C07C43/295 ,  C07C69/007 ,  C07C69/54

Abstract: A polymerizable vinylester composition is described which comprises at least three monomers and oligomers, said composition comprising: 2-95% by weight of: diaryl compounds comprising at least two aryl groups linked directly together or bridged by a linking group, each of said at least two aryl groups having a vinyl group attached thereto, 2-65% by weight of: a methacrylic acid ester of a vinyl-substituted sec-ethylol-diaryl oxide or its thioether or methine or biphenyl counterpart, and 1-35% by weight of: dimethacrylic acid esters of bis-[4-(1-hydroxyethyl)aryl] ether, thioether or methine, or their counterparts where aromatic rings are linked together directly, and 2-95% by weight of: unsaturated oligomers, and said reactive composition has less than 1% mol basis of monoaryl phenolic compounds. A method of synthesizing polymerizable divinylaromatic compositions of the invention is described comprising the steps of dehydrating a diol by heating wherein heating said diols is performed in the presence of a sulfonic acid at a concentration of 0.5-10.0 mmole/L in aromatic solvent at the boiling temperature of the reaction mixture in the range of 100-160° C., and then removing at least some water produced by the dehydration reaction.

Abstract translation: 描述了包含至少三种单体和低聚物的可聚合的乙烯基酯组合物，所述组合物包含：2-95重量％的：包含至少两个直接连接在一起或被连接基团连接的芳基的二芳基化合物，每个至少 两个具有乙烯基的芳基，2-65重量％的乙烯基取代的仲 - 羟基 - 二芳基氧化物的甲基丙烯酸酯或其硫醚或次甲基或联苯对应物，以及1-35重量％的： 双 - [4-（1-羟乙基）芳基]醚，硫醚或次甲基的二甲基丙烯酸酯，或其中芳环直接连接在一起的对应物，以及2-95％（重量）：不饱和低聚物，且其反应性组成小于 1％mol的单芳基酚类化合物。 描述了本发明的可聚合二乙烯基芳族组合物的合成方法，该方法包括以下步骤：通过加热使二醇脱水，其中加热所述二醇在芳族溶剂中在0.5-10.0mmol / L的浓度的磺酸存在下进行， 反应混合物的温度在100-160℃的范围内，然后除去由脱水反应产生的至少一些水。

公开(公告)号：US4613619A

公开(公告)日：1986-09-23

申请号：US704491

申请日：1985-02-22

Applicant: Thomas Sleigh ,  David S. Savage ,  John K. Clark

Inventor： Thomas Sleigh ,  David S. Savage ,  John K. Clark

IPC: A61K31/135 ,  A61K31/165 ,  A61K31/215 ,  A61K31/22 ,  A61P9/06 ,  C07C1/22 ,  C07C17/00 ,  C07C33/38 ,  C07C43/215 ,  C07C43/23 ,  C07C43/285 ,  C07C43/295 ,  C07C45/46 ,  C07C45/65 ,  C07C49/792 ,  C07C49/813 ,  C07C49/84 ,  C07C67/00 ,  C07C213/00 ,  C07C215/44 ,  C07C217/52 ,  C07C217/74 ,  C07C217/76 ,  C07C217/90 ,  C07C219/24 ,  C07C219/26 ,  A61K31/235 ,  C07C91/16 ,  C07C93/24 ,  C07C93/26

CPC classification number: C07C1/22 ,  C07C17/35 ,  C07C33/38 ,  C07C43/215 ,  C07C43/23 ,  C07C43/285 ,  C07C43/295 ,  C07C45/46 ,  C07C45/65 ,  C07C49/792 ,  C07C49/813 ,  C07C49/84 ,  C07C2101/08 ,  Y10S514/821

Abstract: The invention concerns novel anti-arrhythmic amino-alcohol derivatives, characterized by the general formula (1) ##STR1## or pharmaceutically acceptable salts thereof, wherein R.sub.1, R.sub.2 and R.sub.3 each independently represent hydrogen, alkyl having 1-6 carbon atoms, alkoxy having 1-6 carbon atoms, acyloxy having 1-6 carbon atoms, hydroxy, halogen or optionally alkyl-substituted amino;R.sub.4 represents hydrogen, hydroxy or alkyl having 1-6 carbon atoms,R.sub.5 represents hydrogen or alkyl having 1-6 carbon atoms,R.sub.6 represents hydrogen, acyl having 1-18 carbon atoms or alkyl having 1-6 carbon atoms,R.sub.7 and R.sub.8 each independently represent hydrogen or alkyl having 1-6 carbon atoms,X represents a direct bond or an oxygen atom, andn and m each independently are integers having a value of 1 or 2, whereby the sum of n and m is 2 or 3.

Abstract translation: 本发明涉及新型抗心律失常氨基醇衍生物，其特征在于通式（1）其中R1，R2和R3各自独立地代表氢，具有1-6个碳原子的烷基 ，具有1-6个碳原子的烷氧基，具有1-6个碳原子的酰氧基，羟基，卤素或任选的烷基取代的氨基; R4表示氢，羟基或具有1-6个碳原子的烷基，R5表示氢或1-6个碳原子的烷基，R6表示氢，具有1-18个碳原子的酰基或具有1-6个碳原子的烷基，R7和R8各自独立地表示 独立地表示氢或具有1-6个碳原子的烷基，X表示直接键或氧原子，n和m各自独立地为具有1或2的整数，由此n和m的和为2或3。

公开(公告)号：US4226887A

公开(公告)日：1980-10-07

申请号：US29970

申请日：1979-04-16

Applicant: Winston S. Marshall ,  William Pfeifer

Inventor： Winston S. Marshall ,  William Pfeifer

IPC: A61K31/085 ,  A61K31/09 ,  C07C17/00 ,  C07C29/40 ,  C07C43/215 ,  C07C43/285 ,  C07C43/29 ,  C07C45/00 ,  C07C45/29 ,  C07C45/46 ,  A61K31/015

CPC classification number: C07C17/00 ,  A61K31/085 ,  A61K31/09 ,  C07C17/25 ,  C07C29/40 ,  C07C43/215 ,  C07C43/285 ,  C07C43/29 ,  C07C45/004 ,  C07C45/29 ,  C07C45/46

Abstract: This invention is directed to the use of certain arylacetylene compounds, principally as anti-inflammatory agents but also as anti-pyretic agents and as analgesic agents.

Abstract translation: 本发明涉及某些芳基乙炔化合物，主要用作抗炎剂，还可用作抗热解剂和镇痛剂。

公开(公告)号：US2181119A

公开(公告)日：1939-11-28

申请号：US2181119D

CPC classification number: C07C43/285 ,  C07C41/16

公开(公告)号：US09969689B2

公开(公告)日：2018-05-15

申请号：US15439308

申请日：2017-02-22

Applicant: Peloton Therapeutics, Inc.

Inventor： Darryl David Dixon ,  Jonas Grina ,  John A. Josey ,  James P. Rizzi ,  Stephen T. Schlachter ,  Eli M. Wallace ,  Bin Wang ,  Paul Wehn ,  Rui Xu ,  Hanbiao Yang

IPC: C07C43/29 ,  C07C43/275 ,  A61K31/09 ,  C07D213/85 ,  C07C317/22 ,  C07D213/65

CPC classification number: C07D213/85 ,  A61K31/09 ,  A61K31/10 ,  A61K41/0038 ,  A61P35/00 ,  C07C43/205 ,  C07C43/225 ,  C07C43/23 ,  C07C43/263 ,  C07C43/275 ,  C07C43/285 ,  C07C43/29 ,  C07C205/22 ,  C07C255/54 ,  C07C255/56 ,  C07C311/29 ,  C07C313/06 ,  C07C317/22 ,  C07C317/24 ,  C07C317/32 ,  C07C317/34 ,  C07C317/36 ,  C07C317/40 ,  C07C317/42 ,  C07C317/44 ,  C07C317/46 ,  C07C317/48 ,  C07C323/22 ,  C07C381/10 ,  C07C2602/04 ,  C07C2602/08 ,  C07C2602/10 ,  C07C2603/94 ,  C07D213/65 ,  C07D213/89 ,  C07D231/56

Abstract: The present disclosure relates to HIF-2α inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2α scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.

公开(公告)号：US20170217892A1

公开(公告)日：2017-08-03

申请号：US15439494

申请日：2017-02-22

Applicant: Peloton Therapeutics, Inc.

Inventor： Darryl David Dixon ,  Jonas Grina ,  John A. Josey ,  James P. Rizzi ,  Stephen T. Schlachter ,  Eli M. Wallace ,  Bin Wang ,  Paul Wehn ,  Rui Xu ,  Hanbiao Yang

IPC: C07D213/85 ,  C07C317/22 ,  C07C317/36 ,  C07C381/10

CPC classification number: C07D213/85 ,  A61K31/09 ,  A61K31/10 ,  A61K41/0038 ,  A61P35/00 ,  C07C43/205 ,  C07C43/225 ,  C07C43/23 ,  C07C43/263 ,  C07C43/275 ,  C07C43/285 ,  C07C43/29 ,  C07C205/22 ,  C07C255/54 ,  C07C255/56 ,  C07C311/29 ,  C07C313/06 ,  C07C317/22 ,  C07C317/24 ,  C07C317/32 ,  C07C317/34 ,  C07C317/36 ,  C07C317/40 ,  C07C317/42 ,  C07C317/44 ,  C07C317/46 ,  C07C317/48 ,  C07C323/22 ,  C07C381/10 ,  C07C2602/04 ,  C07C2602/08 ,  C07C2602/10 ,  C07C2603/94 ,  C07D213/65 ,  C07D213/89 ,  C07D231/56

Abstract: The present disclosure relates to HIF-2α inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2α scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.